Global PCR-based Infectious Diseases Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

PCR-based Infectious Diseases Market Size

• The global PCR-based infectious diseases market size was valued at USD 5.05 billion in 2024 and is expected to reach USD 8.42 billion by 2032, at a CAGR of 6.60% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within molecular diagnostic platforms, particularly the widespread use of real-time PCR (Polymerase Chain Reaction) in detecting infectious diseases with high sensitivity and specificity. Increased prevalence of conditions such as influenza, tuberculosis, HIV, hepatitis, and emerging pathogens has driven the clinical demand for rapid, accurate, and scalable diagnostic tools
• Furthermore, rising global awareness of early disease detection, coupled with the expansion of decentralized diagnostic facilities such as point-of-care labs and mobile testing units, is accelerating the uptake of PCR-based Infectious Diseases solutions. These converging factors—supported by public health initiatives, improved healthcare infrastructure, and growing investment in infectious disease surveillance—are significantly boosting the industry's growth across both developed and emerging markets

PCR-based Infectious Diseases Market Analysis

• PCR-based diagnostic tools, which enable the rapid and accurate detection of infectious pathogens through amplification of genetic material, are becoming increasingly vital across clinical and research settings due to their high sensitivity, speed, and ability to detect a wide range of infectious agents, including viruses, bacteria, and parasites
• The growing global burden of infectious diseases, combined with heightened awareness following recent pandemics, is significantly driving demand for PCR-based technologies, particularly in diagnostics for diseases such as COVID-19, tuberculosis, hepatitis, and sexually transmitted infections
• North America dominated the PCR-based infectious diseases market with the largest revenue share of 38.9% in 2024, driven by strong healthcare infrastructure, robust diagnostic capabilities, and early adoption of advanced molecular diagnostic tools. The U.S., in particular, saw substantial growth due to government initiatives, high testing volumes, and continuous technological innovation
• Asia-Pacific is projected to be the fastest growing region in the PCR-based infectious diseases market with a CAGR of 11.3% from 2025 to 2032, owing to expanding healthcare access, rising healthcare expenditure, and growing awareness about early infectious disease diagnosis in rapidly developing countries such as China, India, and Southeast Asian nations
• The Laboratory Based Testing segment dominated the PCR-based infectious diseases market with a share of 68.9% in 2024, supported by centralized lab infrastructure and bulk processing capability

Report Scope and PCR-based Infectious Diseases Market Segmentation     

PCR-based Infectious Diseases Market Trends

Increasing Efficiency and Personalization in Diagnostic Solutions

• A prominent trend shaping the global PCR-based infectious diseases market is the advancement and incorporation of intelligent automation and connected technologies that streamline diagnostic workflows and enhance accuracy
• For instance, automated PCR platforms now integrate with advanced software that can predict infection patterns, provide real-time data analytics, and streamline large-scale testing. These improvements are especially impactful in high-throughput settings such as hospitals, laboratories, and public health testing centers
• Several modern PCR systems now offer cloud-based connectivity that allows for remote monitoring, report generation, and seamless integration with electronic health records (EHRs), improving the speed and coordination of infectious disease management
• In addition, the growing adoption of point-of-care (POC) PCR systems is transforming diagnostics in rural or resource-limited environments by offering fast, lab-quality results without the need for centralized laboratory infrastructure
• Companies such as Roche, Cepheid, and Bio-Rad are continually upgrading their PCR-based infectious disease platforms with user-friendly interfaces and enhanced multiplexing capabilities—enabling simultaneous detection of multiple pathogens from a single sample
• The convergence of software-driven automation and connectivity is redefining user expectations for infectious disease diagnostics by offering personalized, rapid, and more accessible solutions across various healthcare settings, thereby accelerating the global adoption of PCR-based technologies

PCR-based Infectious Diseases Market Dynamics

Driver

Growing Need Due to Rising Infection Burden and Diagnostic Demand

• The increasing global burden of infectious diseases, coupled with the need for rapid and accurate diagnostic tools, is a key driver fueling demand for PCR-based Infectious Diseases solutions
• For instance, the World Health Organization (WHO) reported a surge in tuberculosis (TB) cases globally, with an estimated 10.6 million people falling ill in 2022. PCR-based diagnostic tests, such as GeneXpert, have become critical for rapid detection of TB and drug-resistant strains, significantly improving treatment outcomes and reducing transmission. This rising reliance on PCR for infectious disease detection highlights its growing role in global healthcare systems
• As healthcare systems face mounting pressure to detect and contain infections quickly—especially in hospital and public health settings—PCR technology offers precise pathogen identification, low detection limits, and rapid turnaround times, significantly outperforming traditional culture-based methods
• Furthermore, the increasing popularity of point-of-care (POC) PCR systems in community clinics, emergency care, and remote settings enables broader access to early diagnosis and treatment. This democratization of testing aligns with global health initiatives focused on epidemic preparedness and rural healthcare access
• The convenience of sample-to-answer PCR workflows, automation in pathogen panels, and real-time monitoring capabilities are key features driving their adoption across hospitals, diagnostic labs, and even home-testing scenarios. The growing trend toward decentralized diagnostics and user-friendly platforms is further propelling market growth

Restraint/Challenge

Concerns Regarding Affordability and Data Privacy

• Despite their benefits, high costs associated with PCR-based diagnostic instruments and consumables remain a significant barrier, especially in low- and middle-income countries. Budget constraints within healthcare systems can limit access to advanced molecular testing, impeding widespread implementation 
• In addition, growing concerns around patient data privacy and cybersecurity in connected diagnostic platforms are emerging challenges. Cloud-based PCR systems that transmit or store patient data remotely must meet stringent compliance regulations, and any breach could erode user trust
• For instance, recent reports of cybersecurity vulnerabilities in connected diagnostic platforms have raised concerns regarding data protection, particularly when systems are integrated with broader health information networks
• To address these issues, companies are prioritizing data encryption, secure access protocols, and regular firmware updates. Educational efforts around data handling and transparency are also helping rebuild confidence among healthcare providers and end-users
• Lastly, although prices of PCR-based technologies are gradually falling due to scale and innovation, the perceived high cost compared to antigen-based rapid tests may hinder their uptake in mass screening programs or non-critical applications
• Overcoming these challenges will require collaborative efforts among technology developers, regulators, and public health organizations to improve cost-efficiency, ensure regulatory compliance, and promote equitable access to cutting-edge PCR diagnostics

PCR-based Infectious Diseases Market Scope

The market is segmented on the basis of test type, infection, pathogen, PCR technology, patient type, testing, and end user.

• By Test Type

On the basis of test type, the PCR-based infectious diseases market is segmented into Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCR Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Others PCR Test. The SARS (COVID-19) PCR Test segment dominated the market with a 29.3% revenue share in 2024, driven by sustained post-pandemic testing infrastructure and ongoing demand for respiratory diagnostics.

The Human Papillomavirus (HPV) PCR Test segment is projected to register the fastest CAGR of 11.8% from 2025 to 2032, due to rising awareness about cervical cancer screening and broader public health initiatives.

• By Infection

Based on infection type, the PCR-based infectious diseases market is segmented into viral infection, respiratory tract infection, sexually transmitted infection, hospital acquired infections, and other infections. The viral infection segment accounted for the largest share of 42.1% in 2024, supported by high testing volumes for COVID-19, hepatitis, and HIV.

The hospital acquired infections segment is projected to witness the fastest CAGR of 10.2% from 2025 to 2032, driven by increasing regulatory focus on infection control in healthcare settings.

• By Pathogen

On the basis of pathogen, the PCR-based infectious diseases market is segmented into viral, bacterial, fungal, protozoa, and others. The viral pathogen segment led the market with a 45.7% share in 2024, as PCR remains the gold standard for detecting viral RNA.

The bacterial segment is expected to grow at a CAGR of 9.7% from 2025 to 2032, fueled by the need for rapid diagnostics amid rising antibiotic resistance.

• By PCR Technology

On the basis of technology, the PCR-based infectious diseases market is segmented into RT-PCR, Multiplex PCR, and others. The RT-PCR segment held the largest share of 53.5% in 2024, favored for its high sensitivity and widespread application.

The Multiplex PCR segment is anticipated to expand at the fastest CAGR of 12.6% from 2025 to 2032, owing to its efficiency in simultaneous multi-pathogen detection.

• By Patient Type

On the basis of patient type, the PCR-based infectious diseases market is segmented into geriatric, pediatric, and adults. The adults segment captured the largest share of 48.3% in 2024, as most testing for STIs, hepatitis, and respiratory infections targets this demographic.

The pediatric segment is expected to register a CAGR of 10.4%, driven by expanded pediatric diagnostic programs and newborn screening mandates.

• By Testing

On the basis of testing, the PCR-based infectious diseases market is segmented into laboratory based testing and point of care testing. The Laboratory Based Testing segment accounted for the largest share of 68.9% in 2024, supported by centralized lab infrastructure and bulk processing capability.

The Point of Care Testing (POCT) segment is forecasted to grow at the fastest CAGR of 13.2% from 2025 to 2032, reflecting the shift towards decentralized, rapid testing.

• By End User

On the basis of end user, the PCR-based infectious diseases market is segmented into diagnostic centers, hospitals, academic and research institutes, community health centers, clinics, home healthcare, and others. The hospitals segment led with a 34.8% share in 2024, due to their large patient base and in-house diagnostic capabilities.

The home healthcare segment is expected to grow at a CAGR of 12.1% from 2025 to 2032, propelled by consumer preference for remote testing and availability of portable PCR kits.

PCR-based Infectious Diseases Market Regional Analysis

• North America dominated the PCR-based infectious diseases market with the largest revenue share of 38.9% in 2024, driven by growing demand for rapid diagnostic tools, increased prevalence of infectious diseases, and supportive healthcare infrastructure. The region's strong emphasis on early disease detection, coupled with favorable reimbursement policies, has accelerated the adoption of PCR-based testing in both public and private healthcare settings
• Healthcare providers and patients in the region highly value the accuracy, speed, and versatility of PCR diagnostics, especially in detecting pathogens like SARS-CoV-2, influenza, HIV, and HPV
• This growth is further supported by advanced laboratory infrastructure, rising healthcare spending, and strategic collaborations between biotech firms and diagnostic laboratories, positioning PCR-based diagnostics as a critical component of infectious disease management across North America

U.S. PCR-based Infectious Diseases Market Insight

The U.S. PCR-based infectious diseases market captured the largest revenue share of 79% in 2024 within North America, driven by increasing government initiatives to control infectious disease outbreaks and rising awareness of molecular diagnostics. The U.S. continues to lead in the deployment of point-of-care PCR testing, especially across hospitals, urgent care centers, and diagnostic laboratories. Growing use of multiplex PCR panels and the expansion of telehealth services are also contributing significantly to market growth. In addition, the strong presence of key players like Thermo Fisher Scientific and BD is supporting innovation and widespread availability.

Europe PCR-based Infectious Diseases Market Insight

The Europe PCR-based infectious diseases market is projected to expand at a substantial CAGR during the forecast period, driven by increased focus on antimicrobial resistance surveillance, government-supported molecular screening programs, and pandemic preparedness. The growing shift toward personalized medicine and early diagnostics is fostering the use of PCR technologies in both public hospitals and private laboratories. Countries like Germany, France, and the U.K. are investing in PCR capacity as part of their national health strategies.

U.K. PCR-based Infectious Diseases Market Insight

The U.K. PCR-based infectious diseases market is expected to grow at a noteworthy CAGR, supported by the National Health Service’s (NHS) integration of molecular diagnostics into routine screening programs. Rising prevalence of sexually transmitted infections and respiratory illnesses has led to higher demand for rapid PCR tests across clinics and mobile testing centers. The government’s continued funding for COVID-19 variant surveillance and emerging disease tracking also plays a key role in the market’s progression.

Germany PCR-based Infectious Diseases Market Insight

The Germany PCR-based infectious diseases market is expected to expand at a significant CAGR, thanks to its robust healthcare infrastructure and strong support for biotechnology innovation. The market is benefiting from rapid automation in laboratories, rising geriatric population, and increasing demand for high-sensitivity diagnostic solutions. PCR testing is also being widely adopted in hospitals and diagnostic chains for managing hospital-acquired infections and screening for pathogens like MRSA and C. difficile.

Asia-Pacific PCR-based Infectious Diseases Market Insight

The Asia-Pacific PCR-based infectious diseases market is projected to grow at the fastest CAGR of 11.3% from 2025 to 2032, driven by increasing investments in healthcare infrastructure, government-led infectious disease control initiatives, and rising awareness of early diagnosis in countries like China, India, and Japan. The widespread use of mobile diagnostics, as well as the push for affordable PCR testing kits, is accelerating the uptake across both rural and urban settings.

Japan PCR-based Infectious Diseases Market Insight

The Japan PCR-based infectious diseases market is expanding steadily due to its technologically advanced healthcare system and aging population. High demand for low-invasive diagnostic procedures, increasing government funding for disease surveillance, and the integration of real-time PCR technologies in routine hospital diagnostics are the primary drivers of growth. Japan’s emphasis on AI-powered lab automation and personalized care is also expected to foster further advancements in this sector.

China PCR-based Infectious Diseases Market Insight

China PCR-based infectious diseases market accounted for the largest revenue share in the Asia-Pacific PCR-based Infectious Diseases market in 2024, supported by an expanding middle class, high rates of infection detection, and massive investments in public health infrastructure. China's strong domestic manufacturing base enables cost-effective PCR kits and instruments, facilitating large-scale deployment across hospitals, community clinics, and mobile labs. The government’s focus on pandemic preparedness and biosecurity is expected to sustain growth in the coming years.

PCR-based Infectious Diseases Market Share

The PCR-based infectious diseases industry is primarily led by well-established companies, including:

• DNA Labs India (India)
• DrSafeHands (India)
• Ganesh Diagnostic & Imaging Centre Pvt. Ltd. (India)
• Max Lab (India)
• MicroGen Diagnostics (U.S.)
• pathlab (India)
• The Washington Travel Clinic (U.S.)
• Clarewell Clinics (U.K.)
• AZOVA (U.S.)
• One Life Home Health Care Center (India)
• LalPathLabs (India)

Latest Developments in Global PCR-based Infectious Diseases Market

• In July 2025, Seegene Inc. launched STAgora, a new platform integrating PCR-based diagnostic data with predictive modeling and analytics for real‑time infectious disease tracking globally. The platform supports public health surveillance and outbreak response
• In June 2025, Integrated DNA Technologies (IDT) introduced its PrimeTime Influenza Kit and PrimeTime Research Pathogen Panels, optimized for qPCR influenza detection and multiplex pathogen screening. These solutions were unveiled at ASM Microbe 2025, enabling expanded influenza and pathogen surveillance and research
• In January 2025, Bosch Healthcare Solutions received CE‑IVDR certification for its Vivalytic PCR test, designed to rapidly diagnose bacterial meningitis at the point of care. This regulatory milestone enables wider clinical adoption across Europe
• In June 2025, Qiagen reaffirmed its strategy targeting ~7% annual sales growth through 2028, anchored on its PCR-based infectious disease testing platforms. The company emphasized a focus on tests for conditions such as meningitis, pneumonia, tuberculosis, and gastrointestinal infections

SKU-70470